Abstract
Clinical symptoms and lung function of CF may be influenced by correcting essential fatty acids (EFA) deficiency. Nevertheless, the value of EFA supplementation in CF remains controversial. Objectives The aim of this longitudinal randomized double-blind placebo-controlled clinical trial was to assess the benefits of an oral supplementation with omega-3 on clinical and nutritional status, lung function and exercise tolerance. Methods A supplementation with a triglyceride source of omega-3 (Omega 3 Premium®, Laboratoires Ponroy, France) at a daily dose of 60 mg/kg during 1 year was administered to ΔF508 homozygous CF patients above 5 years of age. Patients were assessed at 3, 6, 9 and 12 months. Lung function was performed at each visit and an exercise test before and at the end of study. Results Of the 16 patients included, 13 completed the study. Six received omega-3 and 7 the placebo. Compared to the control group the cumulative duration of antibiotic therapy decreased in the intervention group at 9 months (24.5 days vs 46.0 days, p=0.02) and at 12 months (26.5 days vs 65.0 days, p Conclusions This longitudinal randomized placebo-controlled study shows some clinical benefits of long-term omega-3 supplementation in CF patients. However, additional studies with larger populations are needed. Supported by a grant from the Belgian Cystic Fibrosis Association.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
